<DOC>
	<DOCNO>NCT02226120</DOCNO>
	<brief_summary>The purpose study collect safety tolerability data LCZ696 eligible PARADIGM-HF patient receive open-label investigational drug .</brief_summary>
	<brief_title>Safety Tolerability During Open-label Treatment With LCZ696 Patients With CHF Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Written inform consent extension must obtain assessment perform . 2 . Patients complete PARADIGMHF ( protocol CLCZ696B2314 ) able safely enrol openlabel trial judge investigator . 1 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer 2 . History hypersensitivity allergy study drug , drug similar chemical class , ACEIs , ARBs , NEP inhibitor well know suspected contraindication LCZ696 3 . Known history angioedema 4 . Requirement simultaneous treatment ACEIs ARBs 5 . Current acute decompensated HF ( exacerbation chronic HF manifest sign symptom may require intravenous therapy ) 6 . Symptomatic hypotension and/or SBP &lt; 100 mmHg Visit 1 ( screen ) 7 . Estimated GFR &lt; 30 mL/min/1.73m2 measure simplified MDRD formula Visit 1 ( screen ) 8 . Presence bilateral renal artery stenosis 9 . Serum potassium &gt; 5.2 mmol/L Visit 1 ( screen ) 10 . Evidence hepatic disease determine one following : AST ALT value exceed 3 x ULN Visit 1 , history hepatic encephalopathy , history esophageal varix , history portacaval shunt 11 . Pregnant nursing ( lactate ) woman 12 . Women childbearing potential 13 . Any condition , identify protocol , opinion investigator likely prevent patient safely tolerate LCZ696 complying requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LCZ696 , chronic heart failure , open-label study , ARNI</keyword>
</DOC>